Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling

Martin Fan, Rohini Sidhu, Hideji Fujiwara, Brett Tortelli, Jessie Zhang, Cristin Davidson, Steven U. Walkley, Jessica H. Bagel, Charles Vite, Nicole M. Yanjanin, Forbes D. Porter, Jean E. Schaffer, Daniel S. Ory

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Niemann-Pick type C (NPC)1 is a rare neurodegenerative disease for which treatment options are limited. A major barrier to development of effective treatments has been the lack of validated biomarkers to monitor disease progression or serve as outcome measures in clinical trials. Using targeted metabolomics to exploit the complex lipid storage phenotype that is the hallmark of NPC1 disease, we broadly surveyed Npc1-/- mouse tissues and identified elevated species across multiple sphingolipid classes that increased with disease progression. There was a striking accumulation of sphingoid bases, monohexosylceramides (MCs), and GM2 gangliosides in liver, and sphingoid bases and GM2 and GM3 gangliosides in brain. These lipids were modestly decreased following miglustat treatment, but markedly decreased in response to treatment with 2-hydroxypropyl-β-cyclodextrin (HP-β-CD), two drugs that have shown efficacy in NPC1 animal models. Extending these studies to human subjects led to identification of sphingolipid classes that were significantly altered in the plasma of NPC1 patients. Plasma MCs and ceramides were elevated, whereas sphingoid bases were reduced in NPC1 subjects. Intervention with miglustat in NPC1 patients was accompanied by striking alterations in plasma (reductions in GM1 and GM3 gangliosides) and cerebrospinal fluid (CSF) (increased MCs) sphingolipids. Similar alterations were observed in the CSF from the NPC1 feline model following HP-β-CD treatment. Our findings suggest that these lipid biomarkers may prove useful as outcome measures for monitoring efficacy of therapy in clinical trials.

Original languageEnglish (US)
Pages (from-to)2800-2814
Number of pages15
JournalJournal of Lipid Research
Volume54
Issue number10
DOIs
StatePublished - Oct 2013

Fingerprint

Niemann-Pick Diseases
Sphingolipids
Biomarkers
G(M2) Ganglioside
G(M3) Ganglioside
Cerebrospinal fluid
Cyclodextrins
Lipids
Plasmas
Neurodegenerative diseases
G(M1) Ganglioside
Ceramides
Liver
Cerebrospinal Fluid
Disease Progression
Brain
Animals
Therapeutics
Outcome Assessment (Health Care)
Clinical Trials

Keywords

  • Metabolomics
  • Neurodegeneration
  • Sphingolipids

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Endocrinology

Cite this

Fan, M., Sidhu, R., Fujiwara, H., Tortelli, B., Zhang, J., Davidson, C., ... Ory, D. S. (2013). Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling. Journal of Lipid Research, 54(10), 2800-2814. https://doi.org/10.1194/jlr.M040618

Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling. / Fan, Martin; Sidhu, Rohini; Fujiwara, Hideji; Tortelli, Brett; Zhang, Jessie; Davidson, Cristin; Walkley, Steven U.; Bagel, Jessica H.; Vite, Charles; Yanjanin, Nicole M.; Porter, Forbes D.; Schaffer, Jean E.; Ory, Daniel S.

In: Journal of Lipid Research, Vol. 54, No. 10, 10.2013, p. 2800-2814.

Research output: Contribution to journalArticle

Fan, M, Sidhu, R, Fujiwara, H, Tortelli, B, Zhang, J, Davidson, C, Walkley, SU, Bagel, JH, Vite, C, Yanjanin, NM, Porter, FD, Schaffer, JE & Ory, DS 2013, 'Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling', Journal of Lipid Research, vol. 54, no. 10, pp. 2800-2814. https://doi.org/10.1194/jlr.M040618
Fan M, Sidhu R, Fujiwara H, Tortelli B, Zhang J, Davidson C et al. Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling. Journal of Lipid Research. 2013 Oct;54(10):2800-2814. https://doi.org/10.1194/jlr.M040618
Fan, Martin ; Sidhu, Rohini ; Fujiwara, Hideji ; Tortelli, Brett ; Zhang, Jessie ; Davidson, Cristin ; Walkley, Steven U. ; Bagel, Jessica H. ; Vite, Charles ; Yanjanin, Nicole M. ; Porter, Forbes D. ; Schaffer, Jean E. ; Ory, Daniel S. / Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling. In: Journal of Lipid Research. 2013 ; Vol. 54, No. 10. pp. 2800-2814.
@article{c6a15a4c98c54a8d948f692ee84b6360,
title = "Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling",
abstract = "Niemann-Pick type C (NPC)1 is a rare neurodegenerative disease for which treatment options are limited. A major barrier to development of effective treatments has been the lack of validated biomarkers to monitor disease progression or serve as outcome measures in clinical trials. Using targeted metabolomics to exploit the complex lipid storage phenotype that is the hallmark of NPC1 disease, we broadly surveyed Npc1-/- mouse tissues and identified elevated species across multiple sphingolipid classes that increased with disease progression. There was a striking accumulation of sphingoid bases, monohexosylceramides (MCs), and GM2 gangliosides in liver, and sphingoid bases and GM2 and GM3 gangliosides in brain. These lipids were modestly decreased following miglustat treatment, but markedly decreased in response to treatment with 2-hydroxypropyl-β-cyclodextrin (HP-β-CD), two drugs that have shown efficacy in NPC1 animal models. Extending these studies to human subjects led to identification of sphingolipid classes that were significantly altered in the plasma of NPC1 patients. Plasma MCs and ceramides were elevated, whereas sphingoid bases were reduced in NPC1 subjects. Intervention with miglustat in NPC1 patients was accompanied by striking alterations in plasma (reductions in GM1 and GM3 gangliosides) and cerebrospinal fluid (CSF) (increased MCs) sphingolipids. Similar alterations were observed in the CSF from the NPC1 feline model following HP-β-CD treatment. Our findings suggest that these lipid biomarkers may prove useful as outcome measures for monitoring efficacy of therapy in clinical trials.",
keywords = "Metabolomics, Neurodegeneration, Sphingolipids",
author = "Martin Fan and Rohini Sidhu and Hideji Fujiwara and Brett Tortelli and Jessie Zhang and Cristin Davidson and Walkley, {Steven U.} and Bagel, {Jessica H.} and Charles Vite and Yanjanin, {Nicole M.} and Porter, {Forbes D.} and Schaffer, {Jean E.} and Ory, {Daniel S.}",
year = "2013",
month = "10",
doi = "10.1194/jlr.M040618",
language = "English (US)",
volume = "54",
pages = "2800--2814",
journal = "Journal of Lipid Research",
issn = "0022-2275",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "10",

}

TY - JOUR

T1 - Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling

AU - Fan, Martin

AU - Sidhu, Rohini

AU - Fujiwara, Hideji

AU - Tortelli, Brett

AU - Zhang, Jessie

AU - Davidson, Cristin

AU - Walkley, Steven U.

AU - Bagel, Jessica H.

AU - Vite, Charles

AU - Yanjanin, Nicole M.

AU - Porter, Forbes D.

AU - Schaffer, Jean E.

AU - Ory, Daniel S.

PY - 2013/10

Y1 - 2013/10

N2 - Niemann-Pick type C (NPC)1 is a rare neurodegenerative disease for which treatment options are limited. A major barrier to development of effective treatments has been the lack of validated biomarkers to monitor disease progression or serve as outcome measures in clinical trials. Using targeted metabolomics to exploit the complex lipid storage phenotype that is the hallmark of NPC1 disease, we broadly surveyed Npc1-/- mouse tissues and identified elevated species across multiple sphingolipid classes that increased with disease progression. There was a striking accumulation of sphingoid bases, monohexosylceramides (MCs), and GM2 gangliosides in liver, and sphingoid bases and GM2 and GM3 gangliosides in brain. These lipids were modestly decreased following miglustat treatment, but markedly decreased in response to treatment with 2-hydroxypropyl-β-cyclodextrin (HP-β-CD), two drugs that have shown efficacy in NPC1 animal models. Extending these studies to human subjects led to identification of sphingolipid classes that were significantly altered in the plasma of NPC1 patients. Plasma MCs and ceramides were elevated, whereas sphingoid bases were reduced in NPC1 subjects. Intervention with miglustat in NPC1 patients was accompanied by striking alterations in plasma (reductions in GM1 and GM3 gangliosides) and cerebrospinal fluid (CSF) (increased MCs) sphingolipids. Similar alterations were observed in the CSF from the NPC1 feline model following HP-β-CD treatment. Our findings suggest that these lipid biomarkers may prove useful as outcome measures for monitoring efficacy of therapy in clinical trials.

AB - Niemann-Pick type C (NPC)1 is a rare neurodegenerative disease for which treatment options are limited. A major barrier to development of effective treatments has been the lack of validated biomarkers to monitor disease progression or serve as outcome measures in clinical trials. Using targeted metabolomics to exploit the complex lipid storage phenotype that is the hallmark of NPC1 disease, we broadly surveyed Npc1-/- mouse tissues and identified elevated species across multiple sphingolipid classes that increased with disease progression. There was a striking accumulation of sphingoid bases, monohexosylceramides (MCs), and GM2 gangliosides in liver, and sphingoid bases and GM2 and GM3 gangliosides in brain. These lipids were modestly decreased following miglustat treatment, but markedly decreased in response to treatment with 2-hydroxypropyl-β-cyclodextrin (HP-β-CD), two drugs that have shown efficacy in NPC1 animal models. Extending these studies to human subjects led to identification of sphingolipid classes that were significantly altered in the plasma of NPC1 patients. Plasma MCs and ceramides were elevated, whereas sphingoid bases were reduced in NPC1 subjects. Intervention with miglustat in NPC1 patients was accompanied by striking alterations in plasma (reductions in GM1 and GM3 gangliosides) and cerebrospinal fluid (CSF) (increased MCs) sphingolipids. Similar alterations were observed in the CSF from the NPC1 feline model following HP-β-CD treatment. Our findings suggest that these lipid biomarkers may prove useful as outcome measures for monitoring efficacy of therapy in clinical trials.

KW - Metabolomics

KW - Neurodegeneration

KW - Sphingolipids

UR - http://www.scopus.com/inward/record.url?scp=84884164889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884164889&partnerID=8YFLogxK

U2 - 10.1194/jlr.M040618

DO - 10.1194/jlr.M040618

M3 - Article

C2 - 23881911

AN - SCOPUS:84884164889

VL - 54

SP - 2800

EP - 2814

JO - Journal of Lipid Research

JF - Journal of Lipid Research

SN - 0022-2275

IS - 10

ER -